A new White House executive order aimed at accelerating research into psychedelic therapies is drawing attention from policymakers, healthcare providers, and veterans’ advocates. The policy focuses in part on fast-tracking clinical trials for treatments such as ibogaine, a substance that has long been stigmatized but is now being studied for its potential to treat post-traumatic stress disorder and addiction.
Jim Maguire, co-founder of Government Market Strategies, said the executive action could meaningfully change how quickly veterans gain access to new treatment options, particularly those who have not responded to existing therapies.
“The recent executive order greatly increased the speed at which clinical trials can be performed,” Maguire said. “Specifically, with VA participation, traditional treatment-resistant veterans will be able to participate when it was previously prohibited.”
For years, many veterans with severe PTSD have faced limited options after exhausting standard treatments. The inclusion of the Department of Veterans Affairs in clinical trials could open the door for broader participation and faster data collection, a shift Maguire believes is critical to moving the field forward.
He pointed to several factors that could accelerate progress, including faster review timelines at the U.S. Food and Drug Administration and strong interest from veterans willing to enroll in studies.
“Faster FDA review, a ready-now community of veterans, and the express intention to move fast sets the stage to demonstrate the efficacy of this once, and currently, illicit and stigmatized clinical treatment for U.S. veterans,” he said.
Still, Maguire stressed that the executive order does not remove the core safeguards that govern drug approval in the United States. Any psychedelic-assisted therapy will still need to meet strict standards before becoming widely available.
“The EO does not waive the safety and efficacy requirements and it is not a ‘legalization’ of psychedelic-assisted therapies,” he said. “Controlled trials are required and the FDA will require evidence-based support for approval. The EO simply directs an expedited yet thorough clinical trial.”
Those regulatory requirements are only one part of the challenge. Cultural attitudes toward psychedelic substances remain a significant barrier, even as scientific interest grows. Maguire said public perception may take time to catch up with clinical research, much as it did with other once-controversial treatments.
“Culturally, the stigma attached to the illegal drug remains,” he said. “It is no different from the cultural shift that took time to complete when medical marijuana entered into the marketplace.”
He added that acceptance will likely depend on clear, measurable outcomes from clinical trials.
“This will ease over time with the achievement of favorable clinically-proven outcomes that sufficiently offset the risk associated with the therapy,” he said.
The executive order is paired with a $50 million federal investment, a level of funding that signals growing interest in alternative approaches to mental health care. If the research proves successful, Maguire believes the impact could extend far beyond veterans.
“Psychedelic-assisted therapy, if approved by the FDA, represents a ‘game changing’ option for all who suffer with mental health disorders as well as those with gripping addictions to substances and activities that further perpetuate poor mental health,” he said.
He framed the issue in terms of overall well-being, arguing that effective treatment must address more than isolated symptoms.
“Whole person care is the only way to make the whole person healthy,” Maguire said. “Healthy people are happier, more productive, and contribute more to society.”
The potential ripple effects, he added, could reshape both public health and the broader economy if outcomes meet expectations.
“If a $50 million federal investment creates a pathway to a healthier and happier population as many expect it will, we will see a shift in generational health that will dramatically and favorably change the social and economic future of our country,” he said.
While questions remain about how quickly psychedelic therapies can move through the approval process, the executive order marks a notable shift in federal priorities. For veterans living with PTSD and other mental health conditions, it may represent an opportunity to access new forms of treatment that were previously out of reach.
